Clinical trials: sponsored by Shanghai Chest Hospital
Peripheral Pulmonary Lesions
Optical Biopsy for Peripheral Pulmonary Lesions
The purpose of the study is to describe confocal laser endomicroscopy (CLE) interpretation criteria for different types of peripheral pulmonary lesions (PPLs), with histopathological correlation, and to perform the validation of…
- Trial name
- NCT06457087
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Chest Hospital
KRAS Mutation-Related Tumors, Advanced Lung Cancer
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in…
- Conditions
- KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor
- Trial name
- NCT06456138
- Testing
- Trametinib, Anlotinib, Tislelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer Stage IIIA, Radiotherapy
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Rationale: Completely resected non-small cell lung cancer (NSCLC) patients with histologically confirmed N2 disease are a heterogeneous population.
- Trial name
- NCT02974426
- Testing
- PORT-first, PORT-last, Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
The purpose of the study is to evaluate the efficacy and safety of multimode thermal therapy for early peripheral lung cancer, and to explore the changes of systemic immune microenvironment after multimode thermal therapy.
- Trial name
- NCT06453889
- Testing
- Multimode thermal therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Chest Hospital
Non Small Cell Lung Cancer
Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients
This is a Phase I exploratory study. The study is divided into two parts (A/B).In part A, the primary endpoint is the determination of the recommended phase 2 dose (RP2D).
- Trial name
- NCT04967079
- Testing
- Trametinib, Anlotinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Neoplasm, Anastomotic Leak
Prediction of Anastomotic Complications and Recurrent Laryngeal Nerve Injury Based on Postoperative Early Endoscopic Evaluation
Analyze the correlation between the conformity of the anatomy (based on endoscopic examination) and postoperative anastomotic fistula and anastomotic stenosis; establish an anastomotic classification; and construct a predictive…
- Conditions
- Esophageal Neoplasm, Anastomotic Leak, Recurrent Laryngeal Nerve Injuries, Anastomotic Stenosis
- Trial name
- NCT06348381
- Testing
- No intervention
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shanghai Chest Hospital
Atrial Fibrillation
Blinded Randomized Controlled Trial of Artificial Intelligence Guided Detection of Intracardiac Thrombus
To determine whether an integrated AI decision support can save time and improve the accuracy of detection of intracardiac thrombus, the investigators are conducting a blinded, randomized controlled study of AI-guided detection…
- Trial name
- NCT06206187
- Testing
- Automated detection of the intracardiac thrombus through deep learning, Electrophysiologist judgment of the intracardiac thrombus
- Where
- China
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical Trial
The investigators will conduct a single-arm prospective study to evaluate the efficacy and safety of neoadjuvant therapy with adebrelimab (SHR-1316) and chemotherapy in patients with resectable esophageal squamous cell carcinoma…
- Trial name
- NCT06178211
- Testing
- Immunotherapy: Adebrelimab, chemotherapy: carboplatin plus nab-paclitaxel
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Esophageal Cancer
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
SCR-ESCC-02 is a multicenter, phase I/II clinical study to investigate the safety and efficacy of induction immunochemotherapy followed by concurrent chemoradiotherapy with anti-PD-1 therapy in patients diagnosed with locally…
- Trial name
- NCT06173986
- Testing
- PD-1inhibitor, nab-paclitaxel + cisplatin, Radiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Extensive-Stage Small-Cell Lung Cancer
To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.
This is an open-label, randomised, multicenter, Phase II study. This study is planned to enroll 90 eligible patients to receive durvalumab combined with up to 4 cycles of etoposide and platinum-based chemotherapy (EP).
- Trial name
- NCT04985851
- Testing
- durvalumab + anlotinib, Durvalumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Application of Mixed Reality Technique for Percutaneous Lung Nodule Localization: A Prospective, Randomized, Controlled Trial
With the popularization of CT screening, the detection rate of small lung nodules has greatly increased. Therefore, the clinical thoracoscopic lung nodule biopsy and sub-lobectomy for radical resection of lung cancer are greatly…
- Trial name
- MR (NCT05715996)
- Testing
- mixed reality guided localization
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Shanghai Chest Hospital
Peripheral Pulmonary Nodules, Lung Cancer
mCBCT in Combination With ENB for the Diagnosis of PPNs
This study aims to evaluate the clinical value of mobile cone-beam CT (mCBCT) in combination with electromagnetic navigation bronchoscopy for the diagnosis of peripheral pulmonary nodules, and to explore the value of mCBCT in…
- Trial name
- NCT05518669
- Testing
- Electromagnetic Navigation Bronchoscopy (superDimension™ Navigation System) and Mobile Cone-Beam CT (Cios Spin)
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Shanghai Chest Hospital
Peripheral Pulmonary Lesion
Diagnostic Value of UTB and TB for PPL
The purpose of the study is to evaluate the diagnostic value and safety of ultrathin and thin bronchoscope (UTB and TB) for peripheral pulmonary lesions (PPLs) without X-ray fluoroscopy.
- Trial name
- NCT04571476
- Testing
- Ultrathin bronchoscope, Thin bronchoscope, Virtual bronchoscopic navigation combined with endobronchial ultrasound
- Where
- China
- Volunteers
- 578 people
- Sponsor
- Shanghai Chest Hospital
Surgical Procedure, Unspecified
RAE Versus MIE in Patients With Esophageal Cancer After Neoadjuvant Therapy
This is a prospectively randomized controlled trial to compare RAMIE and MIE in the treatment for locally advanced ESCC after neoadjuvant therapy.
- Trial name
- NCT06012214
- Testing
- ROBOTIC-ASSISTED ESOPHAGECTOMY
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shanghai Chest Hospital
Persistent Atrial Fibrillation, Heart Failure With Reduced Ejection Fraction
AF Ablation for HF With Reduced EF
This is an open label, multi-center, randomized parallel control clinical trial, to examining thethe clinical outcomes of AF ablation on HFrEF patients with persistent atrial fibrillation.
- Trial name
- NCT05827172
- Testing
- AF ablation, medical therapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Chest Hospital
Non-Small Cell Lung Cancer (NSCLC)
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
This is a multicenter, open label, Phase I/IIB study investigating the efficacy and safety of treatment with dacomitinib plus anlotinib as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) with…
- Trial name
- NCT05271916
- Testing
- Dacomitinib+Anlotinib, Dacomitinib
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Shanghai Chest Hospital
Peripheral Pulmonary Lesion
Evaluate the Diagnostic Value of BTPNA for PPL: a Real-world Study
The study is designed as a multicenter prospective trial of BTPNA for the diagnosis of peripheral pulmonary lesions in the real world.
- Trial name
- NCT04597346
- Testing
- Bronchoscopic Transparenchymal Nodule Access
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Atrial Fibrillation, Persistent
The Chinese Registration Study of Driver Ablation of Persistent Atrial Fibrillation.
This is an open label, multi-center, randomized parallel control clinical trial, to demonstrate the role of driver mechanism in maintenance substrate of persistent atrial fibrillation, and evaluate the clinical outcomes of driver…
- Trial name
- NCT04489004
- Testing
- Driver ablation+CPVI, Stepwise ablation
- Where
- China
- Volunteers
- 1,298 people
- Sponsor
- Shanghai Chest Hospital
Non-Small-Cell Lung Cancer
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
The aim of this phase Ⅱ study is to evaluate the efficacy and safety of Furmonertinib combined with Anlotinib as the first-line treatment in locally advanced or metastatic non-small cell lung cancer with sensitive EGFR mutations.
- Trial name
- FOCUS-A (NCT04895930)
- Testing
- Furmonertinib, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma
Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）
NICE-RT study is a "safety run-in" and phase II trial evaluating the safety and efficacy of Camrelizumab combined with Nab-paclitaxel and Carboplatin and Radiotherapy in patients with resectable locally advanced esophageal…
- Trial name
- NCT05650216
- Testing
- Chemotherapy (nab-paclitaxel AUC=2 and carboplatin 80mg/m2)，Immunotherapy (camrelizumab 200mg)、Radiotherapy(primary lesion and adjacent lymph nodes 41.4Gy， distant lymph node 0.5Gy*4)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital